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 MPH is a very effective treatment for ADHD but there are concerns about potential adverse 
effects of extended treatment on several systems, including growth.  
 
 Long term MPH appears to be associated with a statistically significant impact on height and 
weight in ADHD children and adolescents, but effect sizes are small, with possible minimal 
clinical effect. 
 
 Sensitivity analysis did not reveal a significant effect of dose, age and drug naïvity condition as 
possible clinical moderators 
 
 Data on effect on pubertal maturation, although limited, seem to favour the exclusion of a possible 
drug effect on sexual maturation in ADHD subjects. 
 
 Current clinical practice guidelines indicate the need of a careful assessment of growth parameters 
before starting stimulant treatment and the periodic monitoring using standardised growth charts. 





Background: Methylphenidate (MPH) is an efficacious treatment for ADHD but concerns 











Objectives: To systematically review the literature, up to December 2018, conducting a meta-
analysis of association of long-term (> six months) MPH exposure with height, weight and 
timing of puberty.  
Results: Eighteen studies (ADHD n=4868) were included in the meta-analysis. MPH was 
associated with consistent statistically significant pre-post difference for both height (SMD = 
0.27, 95% CI 0.16-0.38, p <0.0001) and weight (SMD = 0.33, 95% CI 0.22-0.44, p <0.0001) 
Z scores, with prominent impact on weight during the first 12 months and on height within 
the first 24-30 months. No significant effects of dose, formulation, age and drug-naïve 
condition as clinical moderators were found. Data on timing of puberty are currently limited. 
Conclusions: Long-term treatment with MPH can result in reduction in height and weight. 
However, effect sizes are small with possible minimal clinical impact. Long-term prospective 
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Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common 
neurodevelopmental disorders (Polanczyk et al., 2014). It is characterized by two main 
symptom dimensions, inattention and motor restlessness/impulsivity, which are pervasive and 
result in significant functional impairments (APA, 2013). According to international 
guidelines, treatment for ADHD should follow a multimodal approach that combines 
behavioural and pharmacological treatment (NICE, 2018; Pliszka, 2006; Taylor et al., 2004). 
The first-choice medication (Taylor et al., 2004) and the most frequently used treatment for 
ADHD in Europe is Methylphenidate (MPH). Positive effects of methylphenidate and other 
psychostimulants have been reported in numerous studies and meta-analyses, across a range 
of outcomes including core ADHD symptoms (Cortese et al., 2018; Coghill et al., 2017; 
Faraone & Buitelaar, 2010; Storebo et al., 2015). However, their use can be accompanied by 
a range of adverse effects including elevated blood pressure and heart rate (Hennissen et al., 
2017), sleep disturbance, nervousness, reduced appetite, headache and abdominal pain.  
Effects on growth are also prominent among these adverse effects. These include 
weight loss and height gain reduction occurring after extended use (Graham & Coghill 2008; 
Cortese et al., 2013; Storebo et al., 2018). Although many studies have measured the effects 
of clinical treatment with stimulant medications on growth and weight loss, there is as yet no 
clear consensus as to whether observed changes in growth are related specifically to stimulant 
medication or to other causes such as the condition of ADHD itself. Furthermore, the overall 
clinical significance of medication-related reductions in height during development has been 
questioned (Vitiello, 2008) – with researchers arguing that final adult height should be 
considered the ultimate index of growth for a correct evaluation (Jensen et al., 2004). The key 
question for these researchers is whether children treated with medication obtain their 
expected height as adults, or not (Swanson et al., 2017). Studies providing longitudinal data 
suggest that stimulants reduce growth in height by as much as 1 cm/year during the first three 
years of treatment and that this reduction can be clinically significant (Poulton, 2005). Some 
data suggest that these effects attenuate over time so that final adult stature is not affected by 
prior stimulant exposure (Faraone et al., 2008; Biederman et al., 2010; Kramer et al., 2000; 
Peyre et al., 2013). Finally, other authors reported that the height or weight changes might be 
a natural symptom of ADHD rather than a consequence of medication (Spencer et al., 1996; 
Hanc & Cieslik, 2008; Swanson et al., 2007). While, on average, reported effects of 











some children seemingly completely unaffected (Biederman et al., 2010; Findling et al., 
2009; Zachor et al., 2006), whilst others experience significant growth suppression (Pliszka et 
al., 2006; Charach et al., 2006; Zhang et al., 2010; Poulton et al., 2012).  
A recent publication by Swanson and the MTA Cooperative Group re-examined children’s 
physical growth for cost-benefit evaluation and revealed that the “New medicated subgroup” 
was, at the 36 months follow up point, 3.04 cm shorter and 2.71 kg lighter than the “Not 
medicated group” with a growth-related cost persisting into adolescence and adulthood. 
During this last phase of observation, orthogonal comparisons revealed that treated cases 
were shorter than the untreated cases, indicating that height suppression was correlated to 
treatment (Swanson et al., 2018). 
Earlier detailed reviews (Poulton et al., 2005; Faraone et al., 2008) substantially confirmed 
that treatment with stimulants (methylphenidate and amphetamine) in childhood, may reduce 
expected height and weight when only high quality studies are considered (longitudinal 
designs analysing changes in z-scores). Studies that failed to detect effects on growth were 
generally of poor methodological quality. All these reviews, although extensive and very well 
conducted, did not completely resolve the key issues related to the effects of MPH on growth. 
They concluded that more work was still needed in order to both clarify the effects of 
variations in formulation and dosing regime and better understand how individual 
characteristics moderate MPH effects. Thus, following the European Committee for 
Medicinal Products for Human Use (CHMP; 2009) requesting provision for further safety 
information about methylphenidate, specifically asking for more data on the long-term effects 
of MPH on growth and development in children and adolescents, we aimed to perform an 
update on the topic by exploring the recent most relevant published literature and by 
conducting a meta-analysis where data were adequate.  
Compared to previous searches we aimed to specifically explore the effects of 
methylphenidate exposure on growth (excluding other stimulant medications when possible), 
by selecting a reasonable time of treatment exposure (> 6 months) for a mid and long term 
evaluation. As more than ten years have passed since the extensive review performed by 
Faraone et al. (2008) was published, our objective was to integrate new evidences of the last 
ten years with the hypothesis of including more studies with stronger methodologies. This 











heterogeneity to be undertaken through sensitivity analyses in order to address the following 
questions:    
 Is MPH associated with clinically significant reduction in growth in children with 
ADHD?  
 Are such effects moderated/predicted by patient’s characteristics (baseline 
auxological parameters, age, gender)? 
 Do dose and formulation (immediate release vs long acting), length of treatment, 
previous treatment history or continuous versus non-continuous therapy moderate the 
effect of MPH on growth? 
 Does MPH affect the timing of puberty? 
 Does MPH affect body composition and/or bone metabolism? 
 
2 METHODS 
The systematic review was restricted to studies examining the effects of methylphenidate on 
growth in children and adolescents suffering from ADHD. There was no restriction with 
regards to ADHD subtype, presence of co-morbid disorders, gender, or socio-economic status 
of participants.  
Since no long-term randomized clinical trials reporting standardized data on growth 
outcomes are available, for the purpose of this review all observational, open-label, 
retrospective and prospective study designs, with or without a control group were included.  
2.1.1 INCLUSION AND EXCLUSION CRITERIA:  
Studies were eligible for inclusion in a quantitative analysis if they: 
- enrolled subjects with a diagnosis of ADHD formulated according to DSM criteria (DSM-
III, DSM-III-R or DSM-IV) or of Hyperkinetic Disorder according to the previous ICD 
system;  
- reported a continuous length of treatment of at least six months. 
- examined subjects on MPH as a mono-therapy or associated with other stimulant 
medications when it was not possible to distinguish between the two drugs;  











- reported data on humans.  
- Recorded growth parameters and/or data on pubertal maturation in children (≥ 6 and < 12 
years) and/or adolescents (≥ 12 and < 18 years) exposed to MPH, using adequate population-
based norms for height and weight.  
Studies were excluded if: 
- they were restricted only to the exposure of the drug in adulthood;  
- the effects on growth were related exclusively to psycho-stimulants other than MPH; 
- they reported data on animals  
2.1.2 OUTCOME MEASURES 
Only studies clearly reporting Z scores for height and/or weight, expressed as mean and 
Standard Deviation (SD), baseline (pre) and at the endpoint (post), were included into the 
quantitative analysis. The outcome measures were the pre–post treatment change in height 
and weight Z scores related to MPH treatment. Where more than one follow-up measurement 
was performed within the same study, the outcomes of the longest follow-up were recorded 
in order to explore measurements of growth parameters over the longest follow-up interval. 
Where studies included auxological parameters from both MPH and a comparison arm (e.g., 
not medicated ADHD or typically developmental control group), only the parameters for the 
medication treatment group were included in the main analysis. A separate analysis was 
performed including ∆ Standard Mean Difference (SMD) in order to compare the medicated 
and not medicated/non ADHD sample. 
When data were available, we also reviewed the changes in body composition (lean tissue, fat 
masses, fat distribution, bone mineral density, bone turnover) and the onset of pubertal 
maturation. 
 
2.2 SEARCH STRATEGY 
We first searched for the most relevant published reviews on the topic (Faraone et al., 2008; 
Poulton et al., 2005; Ptacek et al., 2009, 2014; Rapport et al., 2002). In a second search we 
considered individual trials published from the 70s up to December 2018 and not included in 
the previous reviews, by using the following research sources (PubMed, MEDLINE via Ovid 











The search strategy involved medical subject headings MeSH and terms as free text word 
(see appendix 1 including a flow chart of the search strategy). 
Articles were all screened by two of the authors (SC, CB) on the basis of title and abstract. 
Assessment of articles for final inclusion was based on full text review. Discrepancies were 
resolved by consensus between the two authors and, in case of disagreement, a third author 
(AZ) acted as arbitrator.  
From each paper the following data were extracted into an Excel file:  
 Characteristics of the studies: year of publication, location, study design, sample size, 
diagnostic criteria;  
 Characteristics of study participants: sex distribution, mean and range of age, number of 
growth data information, whether ADHD were medication naïve at baseline or 
previously exposed to ADHD medications; 
 Characteristics of medication: mean and range doses, formulation, length and continuity 
of treatment; 
 Primary and secondary outcome measurement and time of outcome measurements. 
2.2.1 DATA ANALYSIS  
A quantitative analysis was conducted for those studies which clearly reported Z scores for 
height and/or weight expressed as mean and SD at baseline and after methylphenidate 
treatment. The outcome of the latest follow-up was recorded.  A pre–post within-group 
design was used to meta-analyse medication effects on height and weight. Data were 
analysed using RevMan 5.3 (http://ims.cochrane.org.revman). Given the heterogeneity of 
sample characteristics and design in the included studies, individual effect sizes (ES) were 
calculated by using a random effects model and expressed as SMD with 95% confidence 
intervals. ES of about 0.3 represents a small effect, while an ES of about 0.5 or 0.8 indicate 
respectively a medium and large effect (Cohen, 1977)..Heterogeneity was assessed using the 














Tables I and II summarise the main information of the 18 studies included in the quantitative 
analysis of this systematic review.  
 
3.1 CHARACTERISTICS OF THE STUDIES INCLUDED 
Included studies were conducted between 1976 and 2016 with publication years ranging 
between 2003 and 2018.  
Seven studies were performed in the USA, three were from Australia (Poulton & Cowell 
2003; Poulton et al., 2012; 2016), one each from Canada (Charach et al., 2006), Spain (Durà-
Travè et al., 2012), Turkey (Bereket et al., 2005), Italy (Germinario et al., 2013), Sweden 
(Landgren et al., 2017), Denmark (Powell et al., 2015) and Brasil (Granato et al., 2018). Five 
studies were multicentre (Spencer et al., 2006; Faraone et al., 2007; Swanson et al., 2007; 
Lisska et al., 2003; Germinario et al., 2013) with a number of sites ranging between 2 and 87. 
All multi-site studies were conducted in USA apart from Germinario et al., that was 
conducted in Italy. 
The selected studies include a total of 4868 children and adolescents with ADHD (range= 34-
1758; mean= 270.44; SD= 396.60; median = 156); around 80% of included participants were 
male; 3268 of them received, at least at a certain point, MPH treatment. Adequate data on the 
impact of MPH on growth and development were available for 2570 subjects (range= 24-410; 
mean = 142.77; SD = 128.19; median= 88).  
Age of subjects at the beginning of treatment was between 3 and 17 years (mean age 8.79, SD 
= 1.34). Nine studies were limited to pre-adolescent participants (<13 years, mean age= 8.53, 
DS= 0.80), while the rest of the studies examined both children and adolescents up to 18 
years of age.  
Only three studies considered pubertal stage (Tanner & Whitehouse, 1976). Bereket et al., 
(2005) specified that they only included pre-pubertal participants. Zachor et al. (2006), used a 
simplified method to define the pre-pubertal stage (age range between 4.5 and 8.5 years to 
assure that both genders could be included); Diez-Suarez et al. (2017) as well, used a 
simplified method by dividing the sample into children (age range between 6 and 12 years) 











3.1.1 STUDY DESIGNS AND FOLLOW UP 
All the included studies were observational; 9 were defined as retrospective (based on 
reviews of clinical records), one was designated as partially retrospective combining data 
from clinical records and from longitudinal follow up. Eight were prospective.  
Duration of follow-up and mean duration of medication treatment ranged between a 
minimum of 21 months and a maximum of over 72 months (mean: 37.56 months; SD 13.83; 
median 36).  
Eight of the 18 studies included a control sample: in all 1624 subjects (range = 35-394; 
mean= 232; DS= 133.99; median = 260) including either ADHD subjects (n = 360) or non-
ADHD comparisons (n = 1264) or both. Majority of the studies (Harstad et al., 2014; Poulton 
et al., 2012; 2016; Swanson et al., 2007; Lisska et al., 2003; Swanson et al., 2017; Granato et 
al., 2018) included typically neurodevelopmental children as controls, however only three of 
them reported data for a longitudinal comparison (Swanson et al., 2007; Lisska et al., 2003; 
Poulton et al., 2016), while group comparison data where mostly limited only to a single 
observation at baseline in the other studies. Effects of methylphenidate were, in one case 
compared to amphetamines (Pliszka et al., 2006), or, in another case, to atomoxetine 
(Germinario et al., 2013).  
Ten studies selected only initially drug naive patients (Bekeret et al., 2005; Charach et al., 
2006; Germinario et al., 2013; Lisska et al., 2003; Poulton et al., 2012; Poulton &Cowell 
2003; Diez-Suarez et al., 2017; Powell et al., 2015; Poulton et al., 2016, Granato et al., 2018), 
while other 7 included mixed populations that included both drug naive and previously 
treated patients. 
Within the selected 18 studies, the MTA was initially designed as a 14-month randomized 
clinical trial (RCT) to test hypotheses about four treatment strategies in 579 ADHD children 
aged 7-9.9 years: medication management (Med), behavior modification (Beh), their 
combination (Comb), or treatment-as-usual in a community comparison (CC). After the RCT 
phase, the MTA transitioned into an observational long-term follow-up (LTF) phase, during 
which medication use was monitored prospectively in terms of patterns of stimulant 
medication during follow up time as non-medicated, newly medicated, consistently medicated 
and inconsistently medicated (Swanson et al., 2007; Greenfield et al., 2014) or long-term 
patterns of prospective treatment with medication from childhood through adolescence: 











3.1.2 MEDICATION AND THERAPEUTIC DOSAGES 
Eight studies examined methylphenidate (MPH) together with other stimulants 
(amphetamine). One of them (Pliszka et al., 2006) compared a sample of subjects 
continuously treated with MPH for at least one year with a sample treated with 
amphetamines. The other ten specifically examined the effect of MPH but included different 
formulations: seven examined immediate and/or modified release formulations, one a trans-
dermic patch (Faraone et al., 2007), while the other two studies did not specify the 
formulation (Granato et al., 2018; Lisska et al., 2003). Dosages were specified in different 
ways, but mainly as mean daily dose; two studies did not specify the dose. Average daily 
doses varied considerably between studies from 0.48±0.22 mg/kg/day (Germinario et al., 
2013) to 1.31±0.2 mg/kg/day (Durà Travè et al., 2012). Daily average dosages of MPH varied 
from 6 to 85 mg/day, with a mean daily dose of around 29.93 ± 12.14 mg/day. The study 
examining the effect of trans-dermic MPH delivery reported a time of daily exposures to 
treatment of between 9 and 12 hours/day (Faraone et al., 2007). 
3.1.3 PRIMARY OUTCOME MEASURES 
The primary outcome measures varied across studies and were somewhat dependent on the 
period during which the study was conducted. On the basis of our criteria, we were able to 
include only recent studies that expressed the variations in height, weight and BMI through 
standardized age and gender normed z-score parameters.  
Two studies also included the height velocity-SDS as a primary outcome measure (Lisska & 
Rivkees, 2003; Poulton & Cowell, 2003). In addition to more standardised measures, one 
study (Poulton et al., 2012) reported changes in body composition (lean tissue, fat masses, fat 

















3.2 QUANTITATIVE ANALYSIS  
Question 1. Is MPH associated with clinically significant reduction in growth in children 
with ADHD?  
3.2.1 PRE–POST WITHIN-GROUP DESIGN ANALYSES 
Eighteen studies for height (Figure 1) and fourteen studies for weight (Figure 2) met 
inclusion criteria for a quantitative meta-analysis. For both height and weight, all but four 
studies (Diez-Suarez et al., 2017; Harstad et al., 2014; Landgren et al., 2017; Bereket et al., 
2005) reported data on multiple measurements (with a minimum of 2 to a maximum of 6 
different measures). For studies including multiple follow-up times, outcome measures were 
considered at the latest follow up time, varying from a minimum of 21 to a maximum of 72 
months. Stimulant therapy (methylphenidate and amphetamine, when it was not possible to 
distinguish between the two) was associated with a small, however statistically significant 
pre-post difference both for height (SMD = 0.27, 95% CI 0.16-0.38, p <0.0001; Figure 1) and 
weight Z scores, (SMD = 0.33, 95% CI 0.22-0.44, p <0.0001; Figure 2) with a similar large 
between trial heterogeneity (respectively I2= 52% and 44%).  
We also performed a subset of analyses including the studies reporting data at these two 
specific follow-up points: 12-18 months and 24-30 months. 
A moderately significant pre-post difference for weight Z scores, was found when data were 
examined at the 12-18 month follow up (SMD = 0.46, 95% CI 0.29-0.62, p <0.0001; Figure 
3). The largest impact of MPH on weight was usually reported at the end of the first 6 months 
(Poulton et al., 2012; Poulton et al., 2016) and in general within the first 18 -24 months of 
treatment (Poulton & Cowell 2003; Zachor et al., 2006) with a plateau at subsequent follow-
up measures (Powell et al., 2015).  
In terms of height, the most significant pre-post difference, was found when examining data 
at the 24-30 month follow up. These results confirmed the association with a small but highly 
statistically significant pre-post difference for height Z score comparable to the one found at 
the last recorded follow up (SMD = 0.27, 95% CI 0.22-0.31, p <0.0001; Figure 4).  
Three studies reported an impact during the first 6-12 months of treatment with a subsequent 
normalization thereafter (Faraone et al., 2007; Poulton et al., 2012; Poulton et al., 2016). 
Three other studies showed an impact on height later in treatment (Poulton & Cowell, 2003), 











Cowell (2003) reported a normalization of growth within 30-42 months. In a recent work it 
was confirmed that the decline in Z-height growth over time plateaued from 12–47 months, 
though without reaching baseline, but remaining within the expected range for age (Powell et 
al., 2015). Results at the 3 year follow-up of the MTA study confirmed a suppressive effect 
on growth during the first two years of treatment, but suggested that this effect on growth is 
still observable after three years (Swanson et al., 2007).  
3.2.2 ANALYSIS OF CONTROLLED TRIALS 
As stated before, only three studies reported data for a longitudinal comparison of height with 
a control population: not medicated ADHD subjects (Swanson et al., 2007) and typically 
developing siblings (Lisska et al., 2003; Poulton et al., 2016); only two studies reported data 
for weight. In these cases stimulant therapy (methylphenidate and amphetamine) was 
associated with a moderate, statistically significant difference for weight (SMD = -0.47, 95% 
CI -0.75, -0.19, p =0.0010; I2= 0%, Figure 5) but not for height Z scores, (SMD = -0.84, 95% 
CI -1.72, 0.05, p = 0.06, I2=93, Figure 6). 
 
3.3 MODERATORS OF THE TREATMENT EFFECT 
Question 2 and 3. Do patient (baseline auxological parameters, age, gender) and medication 
characteristics (dose, formulation, length of treatment, drug naïve condition) moderate the 
effect of MPH on growth? 
 
A set of sensitivity analyses was performed to assess the effect of possible clinical modifiers 
(MPH as monotherapy, formulation, dose, age, the drug naïve condition) and the effect of the 
study design (retrospective vs prospective). Figure A and Table A. 
 
Ten studies for height (figure 7) and seven for weight (figure 8) examined the effects of MPH 
as a monotherapy confirming the previous results evidencing a small, but statistically 
significant pre-post difference both for height and weight Z-scores. SMD for height was = 
0.23, 95% CI 0.08-0.38, p=0.003; I2=62 while SMD for weight was = 0.24, 95% CI 0.14-
0.35, p<0.0001; I2=10.  
The four studies examining the MPH long-acting formulations (Dura’-Travè et al., 2012; 











difference for weight Z scores (SMD = 0.32, 95% CI 0.18-0.46, p <0.0001; I2 =56), while the 
effect on standardized values for height resulted slightly smaller with a higher heterogeneity 
between trials  (SMD = 0.09, 95% CI 0.03-0.16, p =0.006; I2 =68). 
Sensitivity analysis did not reveal a significant effect of dose on either height or weight mean 
Z scores when considering a mean MPH daily dose of < 30 mg/day vs ≥ 30 mg/day. However 
it is worth noting that some studies evidenced a dose effect by regression models. Charach et 
al. (2006) reported an effect on height for patients treated with doses out of the usual clinical 
range (≥2.5/mg/kg/day) at their 48-month follow-up visit. The MTA study confirmed these 
last results: showing an effect on growth closely related to the dose (Swanson et al., 2007). 
Powell et al., (2015) reported a stronger dose effect, particularly for weight, in patients 
treated with doses ≥ 1.5/mg/kg/day even after 72 months. The studies by Poulton et al., 
showed a dose-related effect to height velocity within the oldest subject group (14-16 years; 
Poulton et al., 2013) and a larger effect on height and weight for larger doses (Poulton et al., 
2016). Interestingly, 2 of the studies reporting a negative impact of stimulants on height did 
not find any correlation with dose (Zhang et al., 2010; Dura’-Travè et al., 2012). Two more 
trials reported a possible correlation between dose and the impact on weight but not height 
(Faraone et al., 2007; Landgren et al., 2017).  
No significant effects were found for age (children <12) or the drug naïve condition.  
Sensitivity analysis did not reveal a significant effect of study design either. A similar pre-
post difference for height Z scores was found when including only studies with a prospective 
design (SMD = 0.25, 95% CI 0.09-0.40, p=0.002; I2 =26) or with a retrospective design  
(SMD = 0.28, 95% CI 0.13-0.44, p=0.003; I2 =63), as well as for weight Z scores (SMD = 
0.34, 95% CI 0.20-0.48, p <0.0001; I2 =0) when including studies with a prospective design 
compared to the retrospective ones (SMD = 0.32, 95% CI 0.14-0.49, p p=0.003; I2 =61). 
 
3.4 GROWTH ADVERSE EFFECTS ON INDIVIDUAL LEVEL 
Considering the importance of possible clinical effects at individual level in clinical practice, 
we also evaluated the available single patient data in terms of appetite suppression, weight 
loss, deviation or decreasing from expected Z scores values and medication cessation. 
Only a minority of studies (5/18; 27.7%) reported individual level data about stimulants 
adverse effects on appetite and growth (either effects on height or weight). The most 










subjects (about 60%) presented with this effect, but only 10 subjects changed medication due 
to this adverse effect.  
Landgren et al., (2017) evidenced that 28 out of 69 (41%) individuals deviated and decreased 
from their expected height Z score values at least 0.5 SD during the treatment period. The 
treatment effect on height development on a group level was minimal, about -0.2 SD 
(subjects with the greater decrease between baseline and follow up were on average taller at 
baseline), but the group of children with height <1.5 SD increased from 5% (5 subjects) to 
10% (8 subjects). In the study by Granato et al., (2018) 3 individuals overall (3.2%) became 
thin, with a minimum weight Z score of −2.81.  
In two patients there were sufficient concerns about growth rates to recommend cessation of 
medication (Poulton et al., 2003) while another subject ceased medication for appetite 
suppression associated to insomnia, tics and headache (Poulton et al., 2016).  
 
3.5 Effect of MPH on puberty  
Question 4. Does MPH affect the timing of puberty? 
Data is currently limited on the impact of either ADHD or MPH on the timing of puberty. 
Using a questionnaire for self-staging of pubertal maturation, Spencer et al. (1996) did not 
detect any obvious influence of methylphenidate in 124 boys with ADHD, the most of them 
treated with stimulant medication. A comparable study of 124 girls with ADHD and a 
matched control group also found no evidence for an influence of MPH on pubertal 
development in girls with ADHD (Biederman et al., 2003). Unfortunately, no information on 
duration of treatment with stimulant medication was reported for this sample, leaving open 
the possibility that the girls had not been treated long enough for either their growth or 
pubertal development to be affected.  
A recent publication from the MTA found no evidence to suggest that stimulant medications 
significantly impacted the timing of puberty. Within this study a subset of participants with 
ADHD (n = 342) and a control group without ADHD (n = 159) completed self-report Tanner 
staging at the 36-month follow-up assessment. Further comparisons were made for the 
participants in the ADHD group who were always (n = 61), never (n = 56), newly (n = 74) 
and inconsistently (n = 116) medicated with stimulants. No statistically significant 











non-ADHD groups at the age of assessment (between 10 and 14 years of age) or among the 
ADHD medication subgroups (Greenfield et al., 2014). 
Poulton et al. (2013) did report a delay in pubertal maturation for 14 to 16-year-old 
adolescents after three years of continuous treatment with stimulant medication.  Of the 65 
boys (age range 12.0-15.9) recruited for the study, the 22 aged 14.0-15.9 years reported 
significantly less advancement in their pubertal development compared to controls with no 
significant correlation with the dose of medication. No significant difference in the stage of 
puberty was found at 12.0-13.9 years of age. These findings suggest that stimulant 
medication may delay the rate of maturation during puberty but not the onset of puberty. 
However, the very small sample sizes limit the generalizability and replication in larger 
groups is required. 
 
3.6 EFFECT OF MPH ON BODY COMPOSITION AND METABOLISM 
Question 5. Does MPH affect body composition and/or bone metabolism? 
Only two trials investigated bone mineral density and bone turnover as an index of changes in 
body composition related to stimulant medication. These reported contrasting results. 
The pilot study conducted by Lahat et al. (2000) compared 10 ADHD subjects treated with 
MPH for 12 to 24 months (mean 13 ± 4) with 10 controls. Laboratory data and bone mineral 
density did not differ between the two groups and no child deviated from his height percentile 
during the treatment period. 
The prospective study of Poulton et al. (2012) examined 34 children aged 4.7-9.1 years, 
newly diagnosed with ADHD and treated with dexamphetamine or methylphenidate. This 
group found significant reductions over 3 years in sex and height corrected Z scores for bone 
mineral content and bone mineral density compared to data gathered from 241 healthy 
children. 
In a later publication Poulton et al., (2016) examined bone age over the first 3 years of 
treatment (dexamphetamine or methylphenidate) in ADHD children compared with their 
healthy siblings (controls). There were no significant growth differences between the two 
groups at baseline. The ADHD patients (n=40) showed no significant maturational delay 
compared to the 22 children belonging to the control group (RUS score: 49 U/year, 95% CI: 










biochemistry and dual-energy X-ray absorptiometry, recording a significant reduction in fat 
(5.61 ± 3.56–4.22 ± 3.09 kg, P < 0.001) and leptin (3.88 ± 2.87–2.57 ± 1.94 ng/ml, P = 
0.017). No medication effect was found on the rate of maturation, which was mostly 
predicted by baseline leptin levels.  
4 DISCUSSION 
ADHD is a chronic condition frequently persisting during late adolescence and adulthood 
(Kooij et al., 2005). As current recommendations are to continue treatment for as long as it is 
needed and helpful (NICE, 2018), patients can, in theory, receive a pharmacological 
treatment for many years with consequent concerns related to potential long-term risks.  
The findings of this review suggest that long term MPH use is associated, at the group level, 
with relatively minor impacts on height and weight in ADHD children and adolescents (pre-
post difference for height Z score: SMD = 0.27 and weight Z score: SMD = 0.35). These 
estimates suggest that stimulants, at a therapeutically daily dose varying between studies 
from 0.48±0.22 mg/kg/day (Germinario et al., 2013) to 1.31±0.2 mg/kg/day (Durà Travè et 
al., 2012) and a mean daily dose of around 29.93 ± 12.14 mg/day, could slow height gain by 
approximately 1.39 cm and weight gain by approximately 1.96 kg for a 10-year-old boy over 
a 2-year period. When considering MPH as a monotherapy (pre-post difference for height Z 
score: SMD = 0.23 and weight Z score: SMD = 0.24) the growth gain decrease can be 
estimated around 1.25 cm less for height and 1.43 kg less for weight for the same 10-year-old 
boy. Over a 2-year-period, MPH could diminish gains in height by 1.65 cm and by 2.6 kg in 
weight for a 14-year-old boy. These effects however seem to be limited in time with a 
subsequent normalization (Poulton & Cowell, 2005; Faraone et al., 2007; Zhang et al., 2010; 
Poulton et al., 2012; Kim et al., 2014, Poulton et al., 2016) and for most individuals are likely 
to have minimal clinical or personal significance. Whether these changes are of concern 
would depend substantially on the individual child stature, as gaining 1,5 cm less could have 
a clinically significant impact only for subject with a height Z score < 2 DS at baseline. 
According to the studies reporting individual data, losses in expected growth were not 
considered clinically significant enough to stop treatment apart from two subjects (Poulton et 
al., 2003). Physicians generally did not advice to discontinue medication, underscoring the 
suggestion that stimulant associated deficits in growth did not pass a threshold that would be 
considered clinically significant. Subjects with the larger impact between baseline and follow 











very short or very light, tended to increase in a minimal part (<10%) from baseline to the last 
observation  (Landgren et al., 2017). 
The extremely heterogeneous nature of the included studies, and the many methodological 
limitations of the currently published papers on this topic, do however limit our ability to 
draw firm conclusions. One of the main methodological limitations in analysing MPH effects 
on growth relates to the definition of outcomes; for this reason we included only recent 
studies preferably expressing the variations in height, weight and BMI through standardized 
age and gender normed Z-score parameters. Methods of outcome measures were in fact an 
issue for earlier studies, particularly those published before the mid-90s. Most of these 
studies considered means of absolute weight and height as the primary outcome with only a 
few using the more standardised measures of percentiles calculated from standardized growth 
charts. Percentiles are still associated with significant imprecision since the averaging of 
percentiles tends to overemphasize the small differences near the mean and underestimate 
similar differences at the extremes (Spencer et al., 1996). More recent publications have 
generally considered Z scores for height, weight and height velocity as primary outcomes. 
These measures are clearly superior to the previous ones: they allow for more valid 
comparisons as they correct for age and sex, avoid mathematical distortions, and show 
similar sensitivity to change at all levels of the curve.  
When used with country specific norms, Z scores can also account for geographic and ethnic 
variability. They are however dependent on accurate population norms. This can be an issue 
for many countries, including some of those used in the US, where much of the research has 
been conducted, using norms that can be out of date and do not account for the secular 
changes in growth measured in the general population over time (www.cdc.gov/growcharts). 
Despite the use of more appropriate outcome measures in recent studies and considering the 
controversial results of the studies of the seventies and the eighties, it is somewhat surprising 
that relatively few long-term studies have been carried out in the last years and that many of 
those that have been conducted are affected by significant methodological limitations, 
precluding an accurate quantitative comparison. 
A further important methodological limitation relates to the statistical management of the age 
of the participants. Since height does not vary linearly with age, the wider the age range of 
the sample being studied, the more vulnerable are direct comparisons of averaged height 
measurements to produce spurious results (Chinchilli et al., 1990). It is also important to 











month periodicity. As a consequence it is generally agreed that at least 4 measurements of 
height, taken six months apart are required to reduce the potential for error when assessing 
growth status.  
A more narrow definition of age of participants within the studies is however not enough to 
get more reliable results. In the majority of the studies included, the mean age at enrolment is 
about 10 years suggesting that many of those included will have been in puberty: during this 
time of development the height velocity increases most and is also the most variable, as the 
timing of puberty varies considerably between otherwise similar individuals. It would 
therefore be most appropriate to stratify the population according to specific stage of pubertal 
status as well as age. Alternatively, the analysis could be performed after excluding those 
subjects who were within puberty. This would however result in the loss of a considerable 
amount of data and leave a considerable hole in our understanding. Since most studies 
included all patients regardless of their pubertal status in their analyses, and none of the study 
actually assessed pubertal status independently of age, this may have diminished the power to 
detect an impact of MPH on growth. It is also important to notice that most studies included a 
male population (about 80% of the sample in the meta-analysis) preventing a clear 
comparison with the opposite gender and partially confounding the accuracy of data when the 
male and female populations were analysed together, considering the different pubertal 
maturation onset of the two genders. 
 
The conclusions from our review should be therefore examined by considering the above 
mentioned limitations in the field and the methodological limitations of our approach. The 
poor quality of the studies limited the possibility to make direct between-study comparisons. 
Most studies did not have a control group and failed to report important information on 
individual data, including the effects of dropouts and previous treatment, or the rating of 
clinical significance of growth effects by physicians, parents, or patients. Other possible 
mediators as prenatal factors, such as toxic exposures, hereditary influences or ethnic and 
socio-demographic composition of their samples were generally not described. Our statistical 
analyses have therefore limited power due to the number of studies available for analysis.  
The mechanisms by which stimulants may affect growth are not completely understood. 
Growth suppression in ADHD children can be a consequence of decreased appetite and 
reduction in caloric intake (Cortese et al., 2013; Ptacek et al., 2014; Vitiello, 2008), 











dopaminergic effect of stimulants with the acute inhibition of growth hormone (De Zegher et 
al., 1993). Another possible mechanism is the effect of stimulants on slowing the growth of 
cartilaginous tissue and consequently the bone growth (Kilgore et al., 1979), with possible 
osteopenic effects for stimulants users (Howard et al., 2017). 
When discussing the long-term effects, it is important to consider that changes, although with 
a generally minimal clinical impact, can vary on an individual basis.  Higher baseline weight 
and height are often associated with a greater impact by stimulant medication, with the 
strongest correlation for weight (Safer et al., 1973; Mattes & Gittelman, 1983; Spencer et al., 
1992; Zeiner et al., 1995; Scherts et al., 1996; Sund & Zeiner 2002; Zachor et al., 2006; 
Faraone et al., 2007) indicating that basal auxological characteristics may represent an 
important clinical correlate. Spencer et al., (2006) divided the sample by using Z scores 
quartiles for weight and height and confirmed a stronger effect for tallest and heavier 
children. Despite data suggesting that overweight and taller children may be more sensible to  
medication effects, a finding that could be seen as reassuring to patients of smaller stature, 
from a clinical point of view it remains important to remember that effects need to be 
measured at an individual level for individual patients.  
Time of follow-up represents another important variable, when evaluating the possible impact 
of stimulants on growth: medication effects tend to attenuate over time both for weight and 
height. According to the results of previous reviews (Poulton et al., 2005; Vitiello, 2008), 
effects on height would manifest later in time with respect to weight (Faraone et al., 2007; 
Spencer et al., 2006; Lisska & Rivkees, 2003), with a similar trend of generally remitting in 
time (Poulton & Cowell, 2003; Klein & Manuzza, 1988; Safer et al., 1973), and time of 
follow up appears to be influenced by the condition of drug-naïvity at the beginning of the 
study. Drug naïve subjects have been shown to present a greater weight and BMI loss with 
MPH transdermal delivery system (Faraone et al., 2007). This characteristic pattern and the 
possible normalization of the auxological parameters over time may explain the negative 
results deriving from the studies including subjects already on stimulants and not drug naïve 
patients (Pliszka et al., 2006). The recent study by Powell et al. (2015) confirms this trend, 
with a temporary lag halt in growth and a Z height growth plateau after 12-47 months of 
follow up in a population of 410 drug-naïve ADHD subjects. 
Although our sensitivity analysis did not reveal an effect for dose when setting the limit of a 
MPH dosage < vs ≥ 30 mg/day, it is important to evidence that several studies have shown 











more predictive of height deficits (Charach et al., 2006; Lisska & Rivkees, 2003; Pliszka et 
al., 2006; Faraone et al., 2007; Poulton et al. 2013; Powell et al., 2015; Diez-Suarez et al., 
2017; Poulton et al., 2016). In the Preschool ADHD Treatment Study (PATS study; Swanson 
et al., 2006), preschool children receiving prolonged treatment (n= 95), showed a yearly 
height deficit of about 20% (-1.38 cm / year) and a weight deficit of about 55% (-1.32 Kg / 
year) than expected, regardless of the administered dose (mean dose 14 mg/day). This finding 
could be explained by the young age of the sample evidencing a possible higher sensitivity to 
MPH according to the age range of patients, with particular attention to the younger children.  
Safety findings on growth parameters from a recent open-label 2-year lisdexamfetamine 
dimesylate trial in ADHD subjects aged 6–17 years (N=314) appear consistent with previous 
studies of stimulant medications (Banaschewski et al., 2018). Mean weight, height and body 
mass index Z-scores transiently decreased over the first 36 weeks of the study and then 
stabilised, with no evidence of delayed onset of puberty.  
In order to minimize growth adverse events, one of the recommended strategies by clinical 
guidelines (NICE, 2018; Taylor et al., 2004), is to plan a break from medication, referred as a 
“drug holiday” (van de Loo- Neus, Rommelse, & Buitelaar, 2011; Ibrahim et al., 2015). 
A recent comprehensive search of the literature identified 22 studies published from 1972 to 
2013 with the aim to map the experience of drug holidays from ADHD medication. The 
authors found evidence for a positive impact on child growth with longer breaks from 
medication, and shorter breaks could reduce insomnia and improve appetite (Ibrahim & 
Donyai 2015). While older studies suggested that withdrawal or interruption of treatment 
may attenuate the suppressive effect of stimulants on growth due to a rebound phenomenon 
(Safer et al., 1972), with significant effects both on height (Klein et al., 1988) and weight 
(Satterfield et al., 1979), more recent studies, on the other hand, do not support the hypothesis 
of a rebound effect of growth after suspension of treatment or did not confirm a positive 
correlation with "drug holiday" (Pliszka et al., 2006; Spencer et al., 2006; Lisska & Rivkees, 
2003; Poulton et al., 2003; Vitiello et al ., 2008).  
The discrepancy between these results can potentially be reconciled when one takes into 
account that those studies that reported correlations often examined together both drug naïve 
and subjects on treatment from a long time. On the other hand, the studies that did not find a 
correlation often did not control the drug holiday in detail, leaving it to the parents to decide 











suspension (weeks vs. months). 
The ultimate index of growth is whether or not an individual reaches their target height 
(expected height as an adult); however none of the selected longitudinal studies included the 
reaching of target height (estimated as a genetic variable taking into account parental height) 
at the end of development as the main outcome. The majority of studies in adult patients 
treated with psychostimulants as children suggest that final height may not be significantly 
impaired, although, in the light of more recent publications (Swanson et al., 2017), this 
hypothesis still remains uncertain and requires further investigation. Biederman et al. (2010) 
in their case-control study with a ten-year follow up, did not find any evidence that stimulant 
treatment could affect final adult height in a sample with a mean age about 21 years. A recent 
search from the National Epidemiologic survey on Alcohol and Related Conditions 
(NESARC) data collected in 2004-2005, confirmed the absence of any significant difference 
in the final adult height in ADHD subjects treated with stimulants during the developmental 
age (n = 216), compared to ADHD never treated with stimulants (n=591) and a control 
sample (n = 34652; Peyre et al., 2013). This finding was further confirmed in a recent 
longitudinal study comparing 243 ADHD to 394 controls. No statistically significant 
differences in adult height were found between the two groups (Harstad et al., 2014).  
The recent publication of MTA outcomes in early adulthood (25 years of age; Swanson et al., 
2017) however contradicts the previous findings, with the ADHD group reported to be 1.29 ± 
0.55 cm shorter than the control group and showing a higher impact on height for subjects 
constantly treated compared to the ADHD sample discontinuing medication. This 
discrepancy of findings of MTA with the other studies appears to be related to changes in the 
clinical use of medication and differences in the cumulative dose, to the adequate separation 
of treated and untreated ADHD subjects and to the average age of treatment initiation.  
All this information should be however read in the context of different potential confounding 
factors including epigenetics (i.e. low birth weight of the child and of their parents and 
grandparents), the positive secular trend of growth, the progression age of menarche and a 
possible genetic condition known as constitutional delay of growth and puberty (CDGP, 
Howard 2018). This is a relatively frequent condition  (2-3% of children), generally self 
limited and representing the extreme end of normal pubertal timing, and the commonest 
cause of delayed puberty in both boys and girls associated with adverse health outcomes 
including short stature, reduced bone mineral density and compromised psychosocial health 











methylphenidate-treated patients to exclude such possible confounding variables. However, 
future progress in gene discovery and technical developments may facilitate the availability 
of genetic diagnosis as part of clinical care for patients on a pharmacological treatment and a 
possible condition of self-limiting delay puberty. At the moment, studies using a self-
controlled case series design could be useful in giving more information about data at an 
individual level, in order to obtain more precise indication for clinical practice for the 
management of possibly more vulnerable subjects. 
 
5 CONCLUSIONS 
Results from the present review reveal that long-term treatment with methylphenidate might 
be associated with a slight growth deficit, in particular with respect to height, with a minimal 
clinical impact and which generally remits in adulthood. It is however possible that a 
clinically significant and meaningful impact may be observed on a small minority of 
individuals.  The clinical meaning of a height deficit must be examined in the context of the 
advantages deriving from medication and the magnitude of the deficit: some caveat about 
groups of individuals who may be more severely affected is important and caution should be 
used in more vulnerable subjects (i.e.: the younger ones or the shortest ones with low baseline 
height or familiar low height as well as subjects showing a decreasing curve in height 
development). As specifically stated in the last NICE guidelines (2018) a planned break in 
treatment over school holidays should be offered if subjects’ height is significantly affected 
by medication over time. 
The impact of methylphenidate on weight is significantly less worrying, as it may change 
during the whole life. The limited data on pubertal maturation available at the moment seem 
to favour the exclusion of a possible drug effect on sexual maturation in treated ADHD 
subjects. 
Considering the identified gaps in the current literature and the concerns form the European 
Medicine Agency, in 2012 the European Commission granted funding for a large research 
projects on long term safety of methylphenidate: the ‘‘Attention Deficit Hyperactivity 
Disorder Drugs Use Chronic Effects “ (ADDUCE; http://adhd-adduce.org). The project 
includes a Work Package aimed to conduct a 2-year prospective cohort study with 











developing children and adolescents) to directly address scientific questions about 
prevalence, clinical significance, development and moderating and/or mediating factors of 
four specific classes of potential long-term adverse effects of MPH (growth, neurological, 
psychiatric and cardiovascular health), with height velocity, as a primary outcome (Inglis et 
al., 2016). This large long-term study, including different control groups, should provide 
more suitable evidence compared to the ones currently available. It has now been completed 
and the results are currently being analysed for publication. 
In conclusion and taking into account continuing uncertainties we do not feel that there is at 
the current time any evidence to suggest a need to change current clinical practice guidelines 
for monitoring of growth and pubertal parameters in children on stimulant medication. These 
all support the careful assessment of the growth parameters before starting stimulant 
treatment and the periodic monitoring through repeated measurement of weight and height 
and subsequent plotting of these on standardised growth charts. Particular caution should be 
taken in pre-school children where adverse effects are more likely and the final dose of 
methylphenidate should be achieved progressively, on the basis of the minimum effective 
dose for optimal treatment (Swanson et al., 2006; Graham et al., 2011; Banaschewski et al., 
2006). 
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Table I. Characteristics of the studies included into the quantitative analysis 
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H: height; W: weight; FU: Follow Up; M: males; PHV: Peak Height Velocity; ^ = Patients with decrease in relative weight within the first 12 months experienced a more profound relative weight loss.; patients with weight loss in the first year experienced a more serious 












6.3 FIGURE A. HARVEST PLOT  
Graphical representation of possible clinical correlation within the studies. Numbers are the number of studies examining the variable expressed in the row.  








































Moderators of treatment effect Height Weight 
MPH as monotherapy YES YES 
MPH formulation YES YES 
MPH dose NO NO 
Subjects age NO NO 
Drug naive condition NO NO 




























































Figure 3. Forest plot with pre-post SMD (=ES) and homogeneity statistics for meta-analysis of weight (MPH and AMP, 12-18 months of follow up). 
  
Pre–post within-group design analyses for weight with stimulant therapy (methylphenidate and amphetamine) at the 12-18 months follow up assessment. 
 
Figure 4. Forest plot with pre-post SMD (=ES) and homogeneity statistics for meta-analysis of height (MPH and AMP, 24 months of follow up). 
  
 









































Figure 7. Forest plot with pre-post SMD (=ES) and homogeneity statistics for meta-analysis of height (MPH).   
 
Pre–post within-group design analyses for height with MPH as mono-therapy. 
 
Figure 8. Forest plot with SMD (=ES) and homogeneity statistics for meta-analysis of weight (MPH). 
 
 
Pre–post within-group design analyses for weight with MPH as mono-therapy. 
 
Fig. 1-4 and 7-8. Forest plots with pre-post standardized mean differences  SMDs (ES) and homogeneity statistics for meta-analyses of height and weight Z scores. The forest plots represent each 
study in the meta-analysis, plotted according to the SMD. The green box on each line shows the SMD for each study. The size of the box stands for the size of the sample size. The black diamond at 
the bottom of the graph shows the average SMD of all studies of all medications. If a green box or the black diamond stands on the right side of the middle line, this represents a higher Z score on 
the pre-test in comparison with the post-test, so a decrease. A box/diamond on the left side of the middle line represents a higher Z score on the post-test in comparison with the pre-test, so an 
increase. If the green box or the black diamond crosses the middle line, then this study reported no significant effect.  
Fig. 5,6. Forest plots with standardized mean differences SMDs (ES) and homogeneity statistics for meta-analyses of height and weight Z scores in controlled trials. If a green box or the black 











6.5 APPENDIX 1 
 
Medical subject headings MeSH and terms as free text word used for the search 
 
“MPH”: Methylphenidate OR methylphenidate hydrochloride OR methylphenidate hcl OR metadata OR 
Medikinet OR methylin OR Ritalin OR equasym OR daytrana OR concerta 
“Side effects”: adverse effects OR adverse reaction OR adverse reactions OR side effect OR side effects OR 
untoward effect OR untoward effects OR adverse drug experience OR adverse drug experiences OR adverse 
drug reaction OR adverse drug reactions OR drug experience report OR drug experience reports OR toxic 
reaction OR toxic reactions OR toxic effect OR toxic effects OR complication OR complications OR undesired 
effect OR undesired effects OR unwanted drug effect OR unwanted drug effects OR “drug toxicity" OR 
“adverse drug reaction" OR “unwanted drug effects" 
“ADHD”: hyperkinetic syndrome OR hyperactivity disorder OR hyperactive child syndrome OR childhood 
hyperkinetic syndrome OR attention deficit hyperactivity disorders OR attention deficit hyperactivity 
disorder OR adhd attention deficit hyperactivity disorder OR addh OR overactive child syndrome OR 
attention deficit hyperkinetic disorder OR hyperkinetic disorder OR adhd OR attention deficit disorder 
hyperactivity OR attention deficit disorders hyperactivity OR child attention deficit disorder OR hyperkinetic 
syndrome OR syndromes hyperkinetic OR hyperkinetic syndrome childhood  
“Growth”: “growth velocity” OR “growth spurt: AND “height “ or “stature”: AND “adult height” OR “adult 






















From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-




































Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMAa) flow diagram on growth effects. 
aPRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement. org). 
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